Molecular Testing Appears To Be Increasing in eNSCLC
An increasing number of patients with eNSCLC currently have access to biomarker testing and targeted therapies, according to the MYLUNG consortium.
Read More
Dissemination (Meeting Coverage)
Black Patients With HCC Less Likely to Receive Curative Treatment
Black patients with HCC are less likely than White patients to receive curative treatment.
Read More
High-Dose Melphalan Conditioning Benefits Patients With Multiple Myeloma
High-dose melphalan conditioning confers survival benefits in patients with extramedullary and non-extramedullary multiple myeloma.
Read More
Targeted Interventions Benefit African Americans With Multiple Myeloma
African Americans benefit from targeted multiple myeloma interventions.
Read More
AI’s Increasing Capacity to Outperform Human Detection of Lung Cancer
AI detects lung cancer better than humans do.
Read More
Understanding the Needs of Patients With Hepatocellular Carcinoma & Their Caregivers
While patients with hepatocellular carcinoma largely felt independent, their caregivers reported burdens related to appointment logistics and emotional support.
Read More
Evaluating Safety & Outcomes of Rapid BCL-2 Inhibitor Titration for CLL
Researchers at the 2024 ASCO Annual Meeting studied the rapid titration of venetoclax for chronic lymphocytic leukemia and mantle cell lymphoma.
Read More
Multiple Myeloma Linked to Higher Costs & Mortality in Patients Admitted for GI Bleeding
Patients with multiple myeloma who were admitted for gastrointestinal bleeding had higher costs and mortality than those without multiple myeloma.
Read More
Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection
Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.
Read More
ALBI Grade, MVI, & Distant Metastases Predict Survival in HCC
HCC survival time is predicted by albumin-bilirubin grade, microvascular invasion, and distant metastases.
Read More
Barriers to Care Delay Costly Multiple Myeloma Treatment
Social determinants of health create barriers that delay access to expensive oral anti-myeloma drugs for people with newly diagnosed multiple myeloma.
Read More
AI and ML Show Promise in Targeting Therapies for Chronic Lymphocytic Leukemia
AI and ML advances chronic lymphocytic leukemia therapies.
Read More
Correlation of Treatment Response with PFS and OS in Patients with R/R CLL or SLL
The following is a summary of “Association between treatment (tx) response and PFS and OS in R/R...
Read More
Analyzing CR as a Surrogate Endpoint for PFS in R/R CLL/SLL
The following is a summary of “Evaluating CR as a surrogate endpoint for PFS in R/R chronic...
Read More
Adjuvant Immunotherapy and Survival Outcomes in Intermediate/Advanced HCC
The following is a summary of “Survival outcomes with adjuvant immunotherapy after hepatic...
Read More
Phosphoproteomics Unveils AB Response in Patients with aHCC
The following is a summary of “Identification of a predictive phosphoproteomic signature of...
Read More
Precision Medicine in HCC: Unveiling Molecular Subtypes through Integrated Multi-Omics Analysis
The following is a summary of “Identification of molecular subtypes for integrated multi-omics...
Read More
Comparing Lenvatinib and Atezolizumab-Bevacizumab in Advanced HCC Treatment
The following is a summary of “Atezolizumab + bevacizumab versus lenvatinib as first-line systemic...
Read More
Study Shows Disparities in Palliative Care Use for Patients With Hepatocellular Carcinoma
Researchers at the 2024 ASCO Annual Meeting found racial and ethnic disparities in palliative care use among patients with advanced hepatocellular carcinoma.
Read More
Fixed-Duration Regimen Substantially Benefits PFS in Patients With CLL/SLL
Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.
Read More